[go: up one dir, main page]

WO2011028344A3 - Interleukin-1 receptor antagonist compositions and methods of making and using same - Google Patents

Interleukin-1 receptor antagonist compositions and methods of making and using same Download PDF

Info

Publication number
WO2011028344A3
WO2011028344A3 PCT/US2010/044040 US2010044040W WO2011028344A3 WO 2011028344 A3 WO2011028344 A3 WO 2011028344A3 US 2010044040 W US2010044040 W US 2010044040W WO 2011028344 A3 WO2011028344 A3 WO 2011028344A3
Authority
WO
WIPO (PCT)
Prior art keywords
making
methods
same
compositions
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/044040
Other languages
French (fr)
Other versions
WO2011028344A2 (en
Inventor
Volker Schellenberger
Joshua Silverman
Willem P. Stemmer
Chia-Wei Wang
Nathan Geething
Benjamin Spink
Wayne To
Jeffrey L. Cleland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/699,761 external-priority patent/US8673860B2/en
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of WO2011028344A2 publication Critical patent/WO2011028344A2/en
Publication of WO2011028344A3 publication Critical patent/WO2011028344A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compositions comprising IL- 1ra linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of IL- 1 -related diseases, disorders, and conditions.
PCT/US2010/044040 2009-08-25 2010-07-30 Interleukin-1 receptor antagonist compositions and methods of making and using same Ceased WO2011028344A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US23683609P 2009-08-25 2009-08-25
US61/236,836 2009-08-25
US24370709P 2009-09-18 2009-09-18
US61/243,707 2009-09-18
US24549009P 2009-09-24 2009-09-24
US61/245,490 2009-09-24
US28095509P 2009-11-10 2009-11-10
US61/280,955 2009-11-10
US28110909P 2009-11-12 2009-11-12
US61/281,109 2009-11-12
US12/699,761 2010-02-03
US12/699,761 US8673860B2 (en) 2009-02-03 2010-02-03 Extended recombinant polypeptides and compositions comprising same

Publications (2)

Publication Number Publication Date
WO2011028344A2 WO2011028344A2 (en) 2011-03-10
WO2011028344A3 true WO2011028344A3 (en) 2011-06-16

Family

ID=43649854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044040 Ceased WO2011028344A2 (en) 2009-08-25 2010-07-30 Interleukin-1 receptor antagonist compositions and methods of making and using same

Country Status (1)

Country Link
WO (1) WO2011028344A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004094A2 (en) 2009-08-24 2016-03-08 Amunix Operating Inc coagulation factor vii compositions and methods for making and using them
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
DK2598526T3 (en) 2010-07-29 2018-11-19 Eleven Biotherapeutics Inc CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
EA035323B1 (en) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. CHEMICAL FACTOR VIII POLYPEPTIDES AND THEIR APPLICATION
HRP20221531T1 (en) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
LT2822577T (en) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CN107496932A (en) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 XTEN conjugate compositions and its method of manufacture
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
LT2956477T (en) 2013-02-15 2021-02-10 Bioverativ Therapeutics Inc. Optimized factor viii gene
CA2903706C (en) 2013-03-13 2024-01-23 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
EA037906B1 (en) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Factor ix polypeptide formulations
US9895420B2 (en) 2013-06-05 2018-02-20 B.G. Negev Technologies And Applications Ltd., At Ben Gurion University IL-1beta propeptide and IL-1Ra chimera and methods of using the same
WO2014210558A1 (en) 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker with xten and its uses thereof
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
DK3091997T5 (en) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
SG11201701803XA (en) 2014-09-26 2017-04-27 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
MX2018001497A (en) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same.
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same
PL3411478T3 (en) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Optimized factor VIII genes
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
EA201991768A1 (en) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
JP7374883B2 (en) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド Nucleic acid molecules and their uses
WO2019126576A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
RS66972B1 (en) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Methods of treating hemophilia a
KR20210027426A (en) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 FGF21 formulation
CN119955796A (en) 2018-08-09 2025-05-09 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use in non-viral gene therapy
EA202191179A1 (en) 2018-10-29 2021-09-09 Байоджен Ма Инк. HUMANIZED AND STABILIZED FC5 OPTIONS TO IMPROVE TRANSPORT THROUGH THE HEMATOENCEPHALIC BARRIER
BR112021010047A2 (en) 2018-12-06 2021-08-24 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
CN115279896A (en) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 Lentiviral vector formulations
CA3157605A1 (en) 2019-11-13 2021-05-20 Volker Schellenberger Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
MX2023000156A (en) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc METHODS FOR THE ELIMINATION OF FREE FACTOR VIII FROM PREPARATIONS OF LENTIVIRAL VECTORS MODIFIED TO EXPRESS SAID PROTEIN.
CA3182372A1 (en) 2020-06-25 2021-12-30 Amunix Pharmaceuticals, Inc. Her-2 targeted bispecific compositions and methods for making and using the same
EP4392443A1 (en) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Optimized factor viii genes
AU2022334711A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Baculovirus expression system
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024072801A1 (en) * 2022-09-26 2024-04-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treating a bacterial infection
CN121013866A (en) 2023-02-10 2025-11-25 阿穆尼克斯制药公司 Compositions targeting Prostate Specific Membrane Antigen (PSMA) and methods of making and using the same
AU2024258990A1 (en) 2023-04-17 2025-10-23 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
WO2025122957A1 (en) 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
WO2007090584A1 (en) * 2006-02-06 2007-08-16 Csl Behring Gmbh Modified coagulation factor vila with extended half-life
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein
WO2007090584A1 (en) * 2006-02-06 2007-08-16 Csl Behring Gmbh Modified coagulation factor vila with extended half-life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VOLKER SCHELLENBERGER ET AL.: "A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner", NATURE BIOTECHNOLOGY, vol. 27, no. 12, 15 November 2009 (2009-11-15), pages 1186 - 1192 *

Also Published As

Publication number Publication date
WO2011028344A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2011028344A3 (en) Interleukin-1 receptor antagonist compositions and methods of making and using same
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
EP2470670A4 (en) Coagulation factor vii compositions and methods of making and using same
EA201190326A8 (en) GROWTH HORMONE POLYPEPTIDES AND METHODS FOR THEIR PRODUCTION AND APPLICATION
WO2009068627A3 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
WO2011123813A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2008074839A3 (en) Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
MX2011008094A (en) Extended recombinant polypeptides and compositions comprising same.
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
EP3461844A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2007021494A3 (en) Albumin fusion proteins
WO2013055888A3 (en) Recombinant human naglu protein and uses thereof
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2009038756A3 (en) Long interspersed nuclear element polypeptide compositions and methods of use thereof
WO2010088463A3 (en) Polypeptides having expansin activity and polynucleotides encoding same
WO2012030845A3 (en) Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814129

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10814129

Country of ref document: EP

Kind code of ref document: A2